

Systemic Anti Cancer Therapy Protocol

Nivolumab with FOLFOX OR CAPOX Advanced UGI

PROTOCOL REF: MPHANFCA
(Version No.: 1.1)

Approved for use in:

Nivolumab in combination with platinum and fluoropyrimidine-based chemotherapy is recommended as **first line** treatment of unresectable locally advanced or metastatic disease as follows:

HER-2 negative **adenocarcinoma** of the stomach or gastro-oesophageal junction or oesophagus either of which expresses PD-L1 with a combined positive score (CPS) of 5 or more. Prior treatment with PD-1 or PD-L1 or PD-L2 or CD137 or OX40 or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is **ONLY** permitted if treatment was discontinued or completed as part of adjuvant therapy without disease progression and at least 6 months has elapsed between the date of the last immunotherapy treatment and the date of first diagnosis of relapse with recurrent or metastatic disease.

OR

Squamous or adenosquamous cell carcinoma of the oesophagus with a tumour cell PD-L1 expression of $\geq 1\%$ and a PD-L1 combined positive score of < 10 . Prior treatment with any antibody which targets PD-1 or PD-L1 or PD-L2 or CD137 or OX40 or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is **NOT** permitted.

ECOG performance status (PS) 0 or 1.

*******Blueteq registration is required*******

Issue Date: August 2023 Review: August 2026	Page 1 of 21	Protocol reference: MPHANFCA
Author: Hala Ghoz	Authorised by: Drugs & Therapeutics Committee	Version No: 1.1

Exclusions

History of pneumonitis, organ transplantation, autoimmune disorders, HIV infection, active hepatitis B or C infection

Active infection requiring systemic treatment

Less than 4 weeks from major surgery

History of clinically severe autoimmune disease (can proceed with immunotherapy if well controlled autoimmune disease at the discretion of the clinical team, this needs to be documented on Meditech)

Patient with active symptomatic CNS disease or carcinomatous meningitis

Dosage:

Nivolumab + FOLFOX

Drug	Dosage	Route	Frequency
Nivolumab	240mg	IV infusion	2 weekly for 12 cycles and then 2 or 4 weekly maintenance* as 240mg or 480mg respectively for 2 years**
Oxaliplatin	85mg/m ²		2 weekly for 12 cycles
Folinic Acid	350mg		
Fluorouracil	400mg/m ²		
Fluorouracil	2400mg/m ²		

OR

Nivolumab + CAPOX

Drug	Dosage	Route	Frequency
Nivolumab	360mg	IV infusion	3 weekly for 6 cycles and then 2, 3 or 4 weekly maintenance as 240mg, 360mg or 480mg respectively for 2 years*
Oxaliplatin	130 mg/m ²	IV infusion	3 weekly for 6 cycles
Capecitabine	625 mg/m ² twice a day	PO	21 days continuous for 6 cycles

* **Nivolumab 480mg 4-weekly should be administered in the maintenance phase** unless there are clinical reasons (risk factors for toxicity are present e.g. pre-existing autoimmune disease or previous immunotherapy-induced toxicity) for using 2 or 3-weekly dosing regimen. Nivolumab is to continue until disease progression or unacceptable toxicity or after 2 years of treatment whichever is first.

Supportive Treatments:

Metoclopramide 10mg oral tablets, up to 3 times a day or as required (total of 5 days supply)

Dexamethasone tablets 4mg twice daily for 3 days

Ondansetron 8mg twice a day for 3 days when required for nausea and vomiting.

Extravasation risk:

Nivolumab – neutral

Oxaliplatin- irritant

Fluorouracil- irritant

Refer to the CCC policy for the [‘Prevention and Management of Extravasation Injuries’](#).

Issue Date: August 2023 Review: August 2026	Page 3 of 21	Protocol reference: MPHANFCA
Author: Hala Ghoz	Authorised by: Drugs & Therapeutics Committee	Version No: 1.1

Dosing in renal and hepatic impairment:

Renal	Oxaliplatin	GFR \geq 30 ml/min: no dose adjustment is needed GFR < 30 ml/min and haemodialysis: consider 50% of the original dose.	
	Fluorouracil	No dose adjustment is needed	
	Capecitabine	GFR (mL/min)	Capecitabine dose
		\geq 60	100% dose
50 to 59		100% dose	
30 to 49		75% dose	
< 30	Omit		
Nivolumab (prior to start of treatment ONLY/Baseline)	GFR \geq 30ml/min proceed with treatment GFR < 30ml/min- use with caution.		

Hepatic	Oxaliplatin	No dose adjustment is needed
	Fluorouracil	Mild (bilirubin $>1.0-1.5 \times$ ULN and any AST or bilirubin \leq ULN and AST $>$ ULN) and moderate (bilirubin $1.5-3 \times$ ULN, with normal or raised AST)- no dose adjustment Severe (bilirubin $>3.0-10 \times$ ULN, with normal or raised AST) - not recommended.
	Capecitabine	No dose adjustment required for hepatic impairment at baseline BUT if bilirubin increases to 3 times ULN or ALT/AST to 2.5 times ULN subsequent to treatment then omit capecitabine until liver function recovers
	Nivolumab (prior to start of treatment ONLY/Baseline)	Administered with caution in patients with: Moderate (total bilirubin $> 1.5 -3 \times$ ULN and any AST) or Severe (total bilirubin $> 3 \times$ ULN and any AST*) hepatic impairment. * Within normal limits or high

Patient Counselling Points

Nivolumab

Women of childbearing potential should use effective contraception throughout treatment and for at least 5 months following the last dose of nivolumab.

Contact the triage team for the following:

- New or worsening cough, chest pain or shortness of breath
- Diarrhoea or severe abdominal pain (with or without blood/mucous)
- Jaundice, severe nausea or vomiting, or easy bruising or bleeding
- Persistent or unusual headache, extreme weakness, dizziness or fainting, or vision changes
- Monitor for signs of infection / sepsis

Capecitabine

- Tablets should be taken 12 hours apart, swallowed whole with plenty of water within 30 minutes of a meal.
- Do not add doses missed due to toxicity onto the end of the cycle. Continue according to the treatment plan and stop taking on the originally scheduled day.
- Take missed doses if remembered within 2 hours of the normal scheduled time. Otherwise continue with the next scheduled dose. Do not double up missed doses
- In case of swallowing difficulties the tablets may be dissolved in 200ml warm water. Once dissolved stir the contents with a spoon and drink immediately. Wash well and reserve the glass and spoon for chemotherapy administration only.

Issue Date: August 2023 Review: August 2026	Page 5 of 21	Protocol reference: MPHANFCA
Author: Hala Ghoz	Authorised by: Drugs & Therapeutics Committee	Version No: 1.1

Administration:

2-weekly Nivolumab + FOLFOX for 12 cycles

Day(s)	Drug	Dose	Route	Diluent and rate
1	Nivolumab	240mg	IV infusion	100mL sodium chloride 0.9%. Infused over 30 minutes in a non-pyrogenic line with a 0.2 micron filter
1	Dexamethasone	8mg	PO	30 minutes before chemotherapy
	Ondansetron	16mg	PO	30 minutes before chemotherapy
CHANGE ADMINISTRATION LINE BEFORE STARTING OXALIPLATIN INFUSION				
1	Oxaliplatin	85mg/m ²	IV	500mL Glucose 5% infusion over 2 hours
Oxaliplatin and Folinic Acid given at same time concomitantly				
1	Folinic Acid	350mg	IV	250mL Glucose 5% infusion over 2 hours
	Fluorouracil	400mg/m ²	IV	Bolus over 5 minutes
1	Fluorouracil	2400mg/m ²	IV	46 hour continuous infusion in Sodium Chloride 0.9%

Followed by maintenance single agent Nivolumab

Day	Drug	Dosage	Route	Diluent and Rate	Frequency
1	Nivolumab	480mg	IV infusion	100mL sodium chloride 0.9%. Infused over 60 minutes in a non-pyrogenic line with a 0.2 micron filter	4 weekly To complete 2 years**
OR					
1	Nivolumab	240mg	IV infusion	100mL sodium chloride 0.9%. Infused over 30 minutes in a non-pyrogenic line with a 0.2 micron filter	2 weekly to complete 2 years**

OR

3-weekly Nivolumab + CAPOX for 6 cycles

Day	Drug	Dosage	Route	Diluent and Rate
1	Nivolumab	360mg	IV infusion	100mL sodium chloride 0.9%. Infused over 30 minutes in a non-pyrogenic line with a 0.2 micron filter
	Dexamethasone	8mg	PO	30 minutes before chemotherapy
	Ondansetron	16mg	PO	30 minutes before chemotherapy
	CHANGE ADMINISTRATION LINE BEFORE STARTING OXALIPLATIN INFUSION WHEN NIVOLUMAB HAS BEEN ADMINISTERED FIRST			
	Oxaliplatin	130mg/m ²	IV infusion	500mL Glucose 5% infusion over 2 hours
Days 1 to 21	Capecitabine	625 mg/m ²	PO	Twice daily, morning and evening continuously

Followed by maintenance single agent Nivolumab

Day	Drug	Dosage	Route	Diluent and Rate	Frequency
1	Nivolumab	480mg	IV infusion	100mL sodium chloride 0.9%. Infused over 60 minutes in a non-pyrogenic line with a 0.2 micron filter	4 weekly To complete 2 years**
OR					
1	Nivolumab	360mg	IV infusion	100mL sodium chloride 0.9%. Infused over 30 minutes in a non-pyrogenic line with a 0.2 micron filter	3 weekly to complete 2 years**
OR					

1	Nivolumab	240mg	IV infusion	100mL sodium chloride 0.9%. Infused over 30 minutes in a non-pyrogenic line with a 0.2 micron filter	2 weekly to complete 2 years**
---	-----------	-------	-------------	--	--------------------------------

****NOTE: Nivolumab 480mg 4-weekly should be administered in the maintenance phase** unless there are risk factors for toxicity are predisposing to toxicity e.g. pre-existing autoimmune disease or previous toxicity, then 2 or 3-weekly regimen may be used instead. Nivolumab to continue until disease progression or unacceptable toxicity or after 2 years of treatment whichever occurs first.

Routine prophylaxis against infusion related reactions is not required. However, monitor during the infusion and treatment given if necessary (antihistamines, steroids etc.). Please refer to the CCC [Hypersensitivity; Management Prevention Policy](#)

For management of **acute cold related dysaesthesia (CRD) or laryngopharyngeal dysaesthesia** as a result of oxaliplatin administration, please refer to 'Main Toxicities' section.

Interactions:

Refer to [SmPC](#) for full list of interactions

Capecitabine/fluorouracil
Phenytoin – potentially toxic levels of phenytoin have been reported- monitor carefully
Warfarin and other coumarin anticoagulants – increased bleeding risk, monitor INR carefully, consider switch to LMWH
Sorivudine and analogues – Potentially fatal interaction – avoid completely
Allopurinol – reduced efficacy of capecitabine – avoid

Increased risk of agranulocytosis with clozapine.

Cimetidine, metronidazole and interferone may increase the plasma level of 5-fluorouracil, thereby increasing the toxicity of 5-fluorouracil.

Fluorouracil enhances the action of other cytostatic drugs and irradiation therapy.

Avoid live vaccines.

Oxaliplatin

Caution should be exercised in patients with a history or a predisposition for prolongation of QT, those who are taking medicinal products known to prolong QT interval (amiodarone, citalopram, domperidone) and those with electrolyte disturbances such as hypokalemia, hypocalcaemia, or hypomagnesaemia. In case of QT prolongation, oxaliplatin treatment should be discontinued.

Nivolumab

The use of systemic corticosteroids and other immunosuppressants before starting nivolumab should be avoided because of their potential interference with the pharmacodynamic activity. But they can be used after starting nivolumab to treat immune-related adverse reactions. Studies have shown show that systemic immunosuppression after starting nivolumab treatment does not appear to preclude the response on nivolumab.

Main Toxicities:

For full details on assessment and management of immune-related toxicities refer to [CCC Immuno-Oncology toxicity specific guidance for adverse event management](#).

Nivolumab	
Immune-Mediated Pneumonitis	Refer to Immuno-Oncology toxicity specific guidance for adverse event management

<p>Pneumonitis occurred in 3% of melanoma patients (including G3 in 0.2%).</p>	
<p>Immune-Mediated Colitis</p> <p>Colitis occurred in 1% of patients (including G3 in 0.5%).</p>	<p>Refer to Immuno-Oncology toxicity specific guidance for adverse event management</p>
<p>Other Immune-Mediated Toxicities:</p> <p>Hypophysitis</p> <p>Nephritis</p> <p>Hyperthyroidism or Hypothyroidism</p> <p>Less frequently:</p> <p>Exfoliative dermatitis, uveitis, arthritis, myositis, pancreatitis, haemolytic anaemia</p>	<p>Monitor LFTs, biochemistry, cortisol and TFTs regularly</p> <p>Refer to Immuno-Oncology toxicity specific guidance for adverse event management</p>
<p>Other non-immune adverse events:</p> <p>Fatigue, anaemia</p> <p>Cough, dyspnoea</p> <p>Nausea, decreased appetite</p> <p>Pruritis, rash</p> <p>Constipation, diarrhoea</p> <p>Arthralgia</p>	<p>Refer to Immuno-Oncology toxicity specific guidance for adverse event management</p>

Laboratory abnormalities: Hyponatraemia, hypocalcaemia, hyperglycaemia, hypertriglyceridaemia	Refer to Immuno-Oncology toxicity specific guidance for adverse event management
Capecitabine / Fluorouracil	
<u>DPD deficiency – leads to severe early fluorouracil/capecitabine toxicity, affects approximately 3% of population, may be life threatening.</u>	
Chest pain, coronary artery spasm	Stop fluorouracil, standard angina investigations, refer to clinical team, if symptoms persist stop permanently
Stomatitis	If mouth ulcers or > grade 2 symptoms develop treat symptomatically, delay treatment until resolved to grade 1 and reduce fluorouracil doses by 20%. See table
Diarrhoea	Treat diarrhoea between cycles symptomatically. If diarrhoea has not resolved by next cycle delay treatment by 1 week. If diarrhoea remains troublesome or more than 1 delay is required reduce both fluorouracil bolus and infusion doses by 20% and continue at the lower dose unless further toxicity occurs - See table
PPE	Treat symptomatically, delay treatment until resolved to grade 1. Reduce fluorouracil doses (bolus and infusion) by 20% for subsequent doses if persistent troublesome PPE. See table below.
Oxaliplatin	
General toxicities	Infusion reactions, neurotoxicity, myelosuppression, mucositis, diarrhoea, nausea and vomiting

Neurotoxicity – see notes below for specific cases	Neurotoxicity	Oxaliplatin dose
	Grade 1 any duration or grade 2 < 7days but resolving before next cycle	85mg/m ²
	Grade 2 persisting for 7 days or Grade 3 resolved by next cycle	65mg/m ²
	Grade 3 persisting to next cycle or any grade 4	Stop oxaliplatin
If oxaliplatin is discontinued, review the infusional dose of fluorouracil and consider increasing to 2800mg/m ²		
Acute cold related dysaesthesia (CRD)	Transient paraesthesia of hands and feet as well as laryngopharyngeal dysaesthesia (unpleasant sensations in throat) is common. Onset is during or within hours of infusion and it resolves in minutes or days. Symptoms are exacerbated by cold – advise patients on suitable precautions e.g. avoid cold drinks. Should not require dose reduction, but if troublesome then infusion duration can be increased to 6 hours (or 4 hours where oncologist and treating team agree dependent on severity of reaction and tolerability of the infusion over this time)	
Laryngopharyngeal dysaesthesia	Stop infusion, provide symptomatic treatment. Resume at slower infusion rate. Give subsequent infusions over 6 hours (or 4 hours where oncologist and treating team agree dependent on severity of reaction and tolerability of the infusion over this time)	

Cumulative dose related sensory neuropathy	Usually occurs after a cumulative dose of 800mg/m ² . It can occur after treatment is completed, is usually reversible taking about 3-5 months to recover
Allergic reactions during infusion	Stop the infusion and call for help. Follow trust anaphylaxis policy. Treat with IV corticosteroid and antihistamine. Discuss continuing with fluorouracil alone or re-challenge with the consultant.

Investigations and treatment plan:

If suspicion of endocrinopathies: request TSH, T4, T3, ACTH, cortisol, LH, FSH, testosterone (men) and prolactin (women)

	Pre	Cycle 1	Prior to Cycle 2	Cycle 2	Prior to cycle 3	Cycle 3	Ongoing
Informed Consent	x						
Clinical Assessment	x		x		x* keep this review if IO added from C2		Prior to cycle 2 then every 6-12 weeks thereafter or as clinically indicated (alternate cycle) can go 12 weeks if well maintained on treatment in selected cases
SACT Assessment (to include PS and toxicities)	x	x		x		x	Every cycle**
OTR	x			x		x	Every cycle prior to Nivolumab treatment. Not required for CAPOX/FOLFOX ONLY cycles Go-ahead NOT required
Immunotherapy bloods as per Meditech order set: FBC, U&E/renal profile, Magnesium, LFTs (AST, ALT and bilirubin), TFTs, cortisol, blood glucose, LDH, CRP	x	x		x		x	Every cycle
Lipid profile (cholesterol)	x					x	At baseline then if clinically indicated
Fatigue profile as per Meditech order set: B12, folate, Iron profile, vitamin D, Zinc, Testosterone (men only), ESR	x						At baseline then if clinically indicated
Full set of observations (<i>BP, heart rate, temperature, respiratory rate and O₂ sats</i>)	x	x		x		x	Every cycle

Issue Date: August 2023 Review: August 2026	Page 14 of 21	Protocol reference: MPHANFCA
Author: Hala Ghoz	Authorised by: Drugs & Therapeutics Committee	Version No: 1.1

PROTOCOL

Creatinine Clearance (Cockcroft and Gault)	x						Every cycle only if baseline CrCL <40ml/min or creatinine increases above 1.5x upper limit of normal or baseline
Dihydropyrimidine dehydrogenase (DPD) deficiency test	x						This test is normally only required if a patient has not had capecitabine, or fluorouracil in the past. However a consultant may still request this test if capecitabine or fluorouracil was not tolerated previously. The result must be available before administration of chemotherapy unless clear documentation from the consultant is available to the contrary. Treatment with capecitabine and fluorouracil is contraindicated in patients with known complete DPD deficiency.
CT scan**	x						Every 12 weeks/if clinically indicated
Trop-T, CK, pro-BNP	x						At baseline and thereafter as clinically indicated Refer to ' Pre-assessment Baseline Cardiac Pathway '
ECG	x						
Weight recorded	x	x		x		x	Every cycle
Height recorded	x						

Formal medical review (can be virtual) to assess the tolerability of treatment and whether treatment should continue (as per NHS England criteria).

****Monitor for symptoms of cardiotoxicity (peripheral oedema, progressive breathlessness, chest pain- please hold treatment and refer patient back to clinical team as a matter of urgency)**

Pregnancy test if applicable

Issue Date: August 2023 Review: August 2026	Page 15 of 21	Protocol reference: MPHANFCA
Author: Hala Ghooz	Authorised by: Drugs & Therapeutics Committee	Version No: 1.1

Dose Modifications and Toxicity Management:

- Dosing delay or discontinuation may be required based on individual safety and tolerability.
- Dose modifications due to toxicity are ONLY permitted on chemotherapy agents (fluorouracil, capecitabine and oxaliplatin).
- Only dosing delay or discontinuation due to toxicity are permitted for nivolumab.
- **If toxicities present, the immunotherapy can be held and the chemotherapy continued at the discretion of the clinical team.**
- Guidelines for permanent discontinuation or withholding of nivolumab doses are contained in ‘Treatment Threshold’ section below.
- Detailed guidelines for the management of immune-related adverse reactions are provided in the [CCC Immuno-Oncology toxicity specific guidance for adverse event management](#).

Issue Date: August 2023 Review: August 2026	Page 16 of 21	Protocol reference: MPHANFCA
Author: Hala Ghoz	Authorised by: Drugs & Therapeutics Committee	Version No: 1.1

Treatment Threshold

Administer treatment on day 1 if:

SACT	Platelets	Neutrophils	Serum Creatinine	Bil	AST/ALT	ALP	TSH and Free T4
Nivolumab	$\geq 100 \times 10^9/L$ (Must be within normal range prior to cycle 1*)	$\geq 1.0 \times 10^9/L$	$\leq 1.5 \times \text{ULN}$ or baseline	$< 3 \times \text{ULN}$	$< 5 \times \text{ULN}$	$< 5 \times \text{ULN}$	Within range or no change from base line
Flourouracil, capecitabine and oxaliplatin			<u>Refer to 'Dosing in renal and hepatic impairment' section for recommended dose modifications for carboplatin and paclitaxel based on individual renal and hepatic function</u>				

ULN = upper limit of normal

If platelets or ANC still below required levels for treatment at week 2, delay treatment again and patient will need assessment and chemotherapy dose reduction as follows

Lowest count since previous cycle	Oxaliplatin dose	Fluorouracil dose
Grade 3 / 4 neutropenia ($< 1.0 \times 10^9/L$) or thrombocytopenia ($< 50 \times 10^9/L$)	65mg/m ²	80% bolus and infusion

Toxicity management:

Detailed guidelines are provided in the CCC clinical network immunotherapy acute oncology guidelines. Systemic high-dose corticosteroid with or without additional immunosuppressive therapy may be required for management of severe immune-related adverse reactions.

Toxicity Grade	Action
Grade 1 Mild	Continue treatment increase monitoring and provide symptomatic treatment.
Grade 2 Moderate	Withhold treatment until resolved to \leq grade 1. Refer to Immuno-Oncology toxicity specific guidance for adverse event management.
Grade 3 and Grade 4 Severe	Withhold treatment. Treatment will be permanently discontinued for any unresolving grade 3-4, severe or life-threatening adverse reaction at the treating clinician's discretion. Refer to Immuno-Oncology toxicity specific guidance for adverse event management.

Fluorouracil dose reductions for non haematological toxicity

	Non haematological toxicities (diarrhoea, stomatitis, PPE)			
grade	0-1	2	3	4
1 st occurrence	100%	80%	50%	Stop treatment
2 nd occurrence	80%	70%	50%	Stop treatment
3 rd occurrence	50%	50%	50%	Stop treatment

References:

Capecitabine Accord 150mg fil-coated tablets, Summary of Product Characteristics, Accord Healthcare Limited. Available from www.medicines.org.uk/emc/medicine. Last updated 17th May 2021.

Fluorouracil 25mg/ml injection, Summary of Product Characteristics, Hospira UK Limited. Available from www.medicines.org.uk/emc/medicine. Last updated 17th May 2021.

Krens S D, Lassche, Jansman G F G A, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. *Lancet Oncol* 2019; 20: e201–08.

NICE TA (TA867) Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma. Published: 11 January 2023.

NICE TA (TA865) Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. Published: 8th February 2023.

OPDIVO 10 mg/mL concentrate for solution for infusion, Summary of Product Characteristics, Bristol Myers Squibb Pharmaceuticals limited. Available from www.medicines.org.uk/emc/medicine. Last updated 4th November 2022.

Oxaliplatin Hospira 5mg/ml concentrate for solution for infusion, Summary of Product Characteristics, Hospira UK Limited. Available from www.medicines.org.uk/emc/medicine. Last updated 13th April 2021.

Issue Date: August 2023 Review: August 2026	Page 20 of 21	Protocol reference: MPHANFCA	
Author: Hala Ghaz	Authorised by: Drugs & Therapeutics Committee	Version No: 1.1	

PROTOCOL

Circulation/Dissemination

Date added into Q-Pulse	8 th November 2023
Date document posted on the Intranet	8 th November 2023

Version History

Date	Version	Author name and designation	Summary of main changes
April 2023	1.0	Gabriella Langton Advanced Pharmacist- NMP	New Regimen Protocol Version 1.0
April 2023	1.1	Hala Ghaz Lead Protocols Pharmacist	Amalgamated V1.0 of both Nivolumab + CAPOX and Nivolumab + FOLFOX into single protocol

Issue Date: August 2023 Review: August 2026	Page 21 of 21	Protocol reference: MPHANFCA	
Author: Hala Ghaz	Authorised by: Drugs & Therapeutics Committee	Version No: 1.1	